Expansion of memory Vδ2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics.

Publication date: Mar 20, 2024

γδ T cells provide rapid cellular immunity against pathogens. Here, we conducted matched single-cell RNA-sequencing and γδ-TCR-sequencing to delineate the molecular changes in γδ T cells during a longitudinal study following mRNA SARS-CoV-2 vaccination. While the first dose of vaccine primes Vδ2 T cells, it is the second administration that significantly boosts their immune response. Specifically, the second vaccination uncovers memory features of Vδ2 T cells, shaped by the induction of AP-1 family transcription factors and characterized by a convergent central memory signature, clonal expansion, and an enhanced effector potential. This temporally distinct effector response of Vδ2 T cells was also confirmed in vitro upon stimulation with SARS-CoV-2 spike-peptides. Indeed, the second challenge triggers a significantly higher production of IFNγ by Vδ2 T cells. Collectively, our findings suggest that mRNA SARS-CoV-2 vaccination might benefit from the establishment of long-lasting central memory Vδ2 T cells to confer protection against SARS-CoV-2 infection.

Open Access PDF

Concepts Keywords
Pathogens Cell
Rapid Cells
Tcr Central
Transcriptomics Cov
Vaccination Effector


Type Source Name
disease VO vaccination
disease IDO cell
disease VO dose
disease VO vaccine
disease IDO immune response
disease IDO production
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO efficiency
disease VO time
disease VO effectiveness
disease MESH infection
drug DRUGBANK Serine
disease VO efficient
disease IDO blood
disease VO population
disease MESH tumors
disease IDO immunodeficiency
drug DRUGBANK Tretamine
disease MESH death
disease VO effective
disease VO immunization
disease VO vaccinated
disease VO vaccine dose
drug DRUGBANK Flunarizine
disease IDO history
disease VO frequency
disease IDO replication
drug DRUGBANK Methionine
disease VO viability
drug DRUGBANK Dimethyl sulfoxide
disease IDO adaptive immune response
disease IDO assay
disease VO dead
disease VO USA
disease VO viable
disease VO company
disease MESH sti
drug DRUGBANK Chromium
disease VO volume
disease VO gene
drug DRUGBANK Pidolic Acid
drug DRUGBANK Coenzyme M
disease VO ANOVA
drug DRUGBANK Proline
drug DRUGBANK Hyaluronic acid
disease MESH seroconversion
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH viral infections
disease MESH influenza
disease MESH AIDS
drug DRUGBANK Thioredoxin
disease VO GatA
pathway KEGG Apoptosis
drug DRUGBANK Ferrous sulfate anhydrous
drug DRUGBANK Guanosine
drug DRUGBANK Tocilizumab
disease MESH cytokine storm
drug DRUGBANK BCG vaccine
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease VO vaccine adjuvant
drug DRUGBANK Natural alpha interferon
disease MESH pulmonary tuberculosis
disease IDO facility

Original Article

(Visited 1 times, 1 visits today)